The effects of ADT + AAP in improving the OS of patients with low tumor burden are slightly lower than those of ADT + ENZA and ADT + APA; however, with the increase in tumor burden, the effects of ENZA, an AR antagonist, decreased gradually, which confirmed that the effects of AR antagonists change with the progression of the disease. This evidence concerns the gene AR and neoplasm.